Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.000
-0.010 (-0.99%)
Aug 27, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Revenue
Actinium Pharmaceuticals had revenue of $35.00M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $35.09M. In the year 2025, Actinium Pharmaceuticals had annual revenue of $90.00K.
Revenue (ttm)
$35.09M
Revenue Growth
n/a
P/S Ratio
0.90
Revenue / Employee
$1,299,630
Employees
27
Market Cap
31.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 90.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 81.00K | -949.00K | -92.14% |
| Dec 31, 2022 | 1.03M | -114.00K | -9.97% |
| Dec 31, 2021 | 1.14M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Radiopharm Theranostics | 10.86M |
| Kyntra Bio | 4.62M |
| BeyondSpring | 1.88M |
| IGC Pharma | 1.11M |
ATNM News
- 13 days ago - Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - PRNewsWire
- 20 days ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 20 days ago - Actinium Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 3 months ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 3 months ago - Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026 - TheFly
- 3 months ago - Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PRNewsWire
- 3 months ago - Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - PRNewsWire
- 3 months ago - Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer - TheFly